BioReperia AB closes Series A Financing Round expanding its Investors Base to Switzerland and Germany

Linköping, Sweden – June 24, 2019

BioReperia AB, a Swedish biotech company active in the fields of Precision Medicine and Drug Discovery, has successfully closed its Series A financing. A selection of new investors such as HEMEX, Almi Invest and private investors, along with existing shareholders, participated in the capital raise.

Read more:

BioReperia AB closes Series A Financing Round expanding its Investor 2019-06-24_FINAL

Marsa Corporate Finance GmbH

c/o HB&P Treuhand AG
St. Alban-Anlage 44
CH  –  4010  Basel
Direkt           +41 76 341 18 76
Email             contact@marsaco.com